Glenmark Launches Triple Fdc Of Teneligliptin + Pioglitazone + Metformin In India For Adults With Type 2 Diabetes & High Insulin Resistance

Glenmark Pharmaceuticals Limited (Glenmark), An Innovation Driven, Global Pharmaceutical Company, Has Launched The First Triple Fixed-Dose Combination Teneligliptin With Pioglitazone And Metformin In India. Teneligliptin Is A Widely Used Dpp4 Inhibitor (Dipeptidyl Peptidase 4 Inhibitor). This Fdc Has Been Launched Under The Brand Name Zita-Piomet, And Contains Teneligliptin (20 Mg) + Pioglitazone (15 Mg) + Metformin (500Mg/1000Mg) In A Sustained Release (Sr) Formulation. This Offers Patients With Type 2 Diabetes The Convenience Of Once Daily Dosing To Improve Their Glycaemic Control And Achieve The Targeted Hba1C Within 24 Weeks. On Occasion Of The Launch, Alok Malik, Evp & Business Head - India Formulations, Glenmark Pharmaceuticals Ltd., Said,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!